Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study

Radiotherapy and Oncology

Volumn 120, Issue 3, 2016, Pages 428-433

  Sturdza, Alina ^a   Pötter, Richard ^a   Fokdal, Lars Ulrik ^b   Haie Meder, Christine ^c   Tan, Li Tee ^d   Mazeron, Renaud ^c   Petric, Primoz ^e   Šegedin, Barbara ^e   Jurgenliemk Schulz, Ina Maria ^f   Nomden, Christel ^f   Gillham, Charles ^g   McArdle, Orla ^g   Van Limbergen, Erik ^h   Janssen, Hilde ^h   Hoskin, Peter ⁱ   Lowe, Gerry ⁱ   Tharavichitkul, Ekkasit ^j   Villafranca, Elena ^k   Mahantshetty, Umesh ^l   Georg, Petra ^a   Kirchheiner, Kathrin ^a   Kirisits, Christian ^a   Tanderup, Kari ^b   Lindegaard, Jacob Christian ^b   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e INSTITUTE OF ONCOLOGY   (Slovenia)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g ST LUKE S HOSPITAL   (Ireland)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ MOUNT VERNON HOSPITAL   (United Kingdom)

^j Faculty of Medicine Chiang Mai University   (Thailand)

^k UNIVERSITY OF NAVARRA   (Spain)

^l TATA MEMORIAL HOSPITAL   (India)

more..

Author keywords

Image guided brachytherapy; Locally advanced cervical cancer; Outcome

Indexed keywords

CISPLATIN;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER DISEASE; BRACHYTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CHEMORADIOTHERAPY; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HIGH RISK CLINICAL TARGET VOLUME; HUMAN; IMAGE GUIDED BRACHYTHERAPY; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; INTESTINE FISTULA; KAPLAN MEIER METHOD; LYMPH NODE; MAJOR CLINICAL STUDY; MORBIDITY; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; ORGANS AT RISK; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RADIOLOGICAL PARAMETERS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; VAGINA BLEEDING; CLINICAL TRIAL; INTERVENTIONAL RADIOLOGY; MIDDLE AGED; PELVIS; PROCEDURES; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; ORGANS AT RISK; PELVIS; RADIOLOGY, INTERVENTIONAL; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84967203022     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2016.03.011     Document Type: Article

References (32)

1. [1] Thomas, G., Improved treatment for cervical cancer – concurrent chemotherapy and radiotherapy. N Engl J Med 340 (1999), 1198–2000.
2. [2] Lanciano, R.M., Martz, K., Coia, L.R., Hanks, G.E., Tumor and treatment factors improving outcome in stage III-B cervix cancer. Int J Radiat Oncol Biol Phys 20 (1991), 95–100.
3. [3] Han, K., Milosevic, M., Fyles, A., Pintilie, M., Viswanathan, A.N., Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys 87 (2013), 111–119.
4. [4] Haie-Meder, C., Potter, R., Van Limbergen, E., et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 74 (2005), 235–245.
5. [5] Pötter, R., Haie-Meder, C., Van Limbergen, E., et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 78 (2006), 67–77.
6. [6] Lindegaard, J.C., Fokdal, L.U., Nielsen, S.K., Juul-Christensen, J., Tanderup, K., MRI-guided adaptive radiotherapy in locally advanced cervical cancer from a Nordic perspective. Acta Oncol 52 (2013), 1510–1519.
7. [7] Tinkle, C.L., Weinberg, V., Chen, L.M., et al. Inverse planned high-dose-rate brachytherapy for locoregionally advanced cervical cancer: 4-year outcome. Int J Radiat Oncol Biol Phys 92 (2015), 1093–1100.
8. [8] Castelnau-Marchand, P., Chargari, C., Maroun, P., et al. Clinical outcomes of definitive chemoradiation followed by intracavitary pulsed-dose rate image-guided adaptive brachytherapy in locally advanced cervical cancer. Gynecol Oncol, 2015.
9. [9] Nomden, C.N., de Leeuw, A.A., Roesink, J.M., et al. Clinical outcome and dosimetric parameters of chemo-radiation including MRI guided adaptive brachytherapy with tandem-ovoid applicators for cervical cancer patients: a single institution experience. Radiother Oncol 107 (2013), 69–74.
10. [10] Pötter, R., Georg, P., Dimopoulos, J.A., et al. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol 100 (2011), 116–123.
11. [11] Tan, L.T., Whitney, D., Coles, C.E., Long term outcome of CT-based Image-Guided Brachytherapy for cervix cancer using the tandem-ring applicator. OMICS J Radiol, S1, 2014, 003.
12. [12] Kang, H.C., Shin, K.H., Park, S.Y., Kim, J.Y., 3D CT-based high-dose-rate brachytherapy for cervical cancer: clinical impact on late rectal bleeding and local control. Radiother Oncol 97 (2010), 507–513.
13. [13] Rijkmans, E.C., Nout, R.A., Rutten, I.H., et al. Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy. Gynecol Oncol 135 (2014), 231–238.
14. [14] Gill, B.S., Kim, H., Houser, C.J., et al. MRI-guided high-dose-rate intracavitary brachytherapy for treatment of cervical cancer: the University of Pittsburgh experience. Int J Radiat Oncol Biol Phys 91 (2015), 540–547.
15. [15] Refaat, T., Castelain, B., Small, W. Jr, et al. Concomitant Chemotherapy with Image-guided Pulsed Dose Rate Brachytherapy as a Definitive treatment modality for Early-stage Cervical Cancer. Am J Clin Oncol 38 (2015), 289–293.
16. [16] Perez, C.A., Grigsby, P.W., Chao, K.S., Mutch, D.G., Lockett, M.A., Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix. Int J Radiat Oncol Biol Phys 41 (1998), 307–317.
17. [17] Landoni, F., Maneo, A., Colombo, A., et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 350 (1997), 535–540.
18. [18] Barillot, I., Horiot, J.C., Pigneux, J., et al. Carcinoma of the intact uterine cervix treated with radiotherapy alone: a French cooperative study: update and multivariate analysis of prognostic factors. Int J Radiat Oncol Biol Phys 38 (1997), 969–978.
19. [19] Jampolis, S., Andras, E.J., Fletcher, G.H., Analysis of sites and causes of failures of irradiation in invasive squamous cell carcinoma of the intact uterine cervix. Radiology 115 (1975), 681–685.
20. [20] Eifel, P.J., Jhingran, A., Brown, J., et al. Time course and outcome of central recurrence after radiation therapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 16 (2006), 1106–1111.
21. [21] Logsdon, M.D., Eifel, P.J., Figo IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy. Int J Radiat Oncol Biol Phys 43 (1999), 763–775.
22. [22] Benedet, J.L., Bender, H., Jones, H. 3rd, Ngan, H.Y., Pecorelli, S., FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 70 (2000), 209–262.
23. [23] Viswanathan, A.N., Dimopoulos, J., Kirisits, C., Berger, D., Potter, R., Computed tomography versus magnetic resonance imaging-based contouring in cervical cancer brachytherapy: results of a prospective trial and preliminary guidelines for standardized contours. Int J Radiat Oncol Biol Phys 68 (2007), 491–498.
24. [24] Bentzen, S.M., Dorr, W., Gahbauer, R., et al. Bioeffect modeling and equieffective dose concepts in radiation oncology–terminology, quantities and units. Radiother Oncol 105 (2012), 266–268.
25. [25] Auth, B., Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0. 2003, DCTD, NCI, NIH, DHMS ( http://ctep.cancer.gov), Publish date: August 9, 2006.
26. [26] Vale, C., Thierny, J.F., Stewart, L.A., Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 26 (2008), 5802–5812.
27. [27] Tanderup, K., Fokdal, L., Sturdza, A.E., et al. Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy in locally advanced cervical cancer. Radiother Oncol 120 (2016), 441–446.
28. [28] Charra-Brunaud, C., Harter, V., Delannes, M., et al. Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study. Radiother Oncol 103 (2012), 305–313.
29. [29] Vale, C.L., Tierney, J.F., Davidson, S.E., Drinkwater, K.J., Symonds, P., Substantial improvement in UK cervical cancer survival with chemoradiotherapy: results of a Royal College of Radiologists’ audit. Clin Oncol (R Coll Radiol) 22 (2010), 590–601.
30. [30] Tan, L.T., Implementation of image-guided brachytherapy for cervix cancer in the UK: progress update. Clin Oncol (R Coll Radiol) 23 (2011), 681–684.
31. [31] Gill, B.S., Lin, J.F., Krivak, T.C., et al. National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements. Int J Radiat Oncol Biol Phys 90 (2014), 1083–1090.
32. [32] Tewari, K.S., Sill, M.W., Long, H.J. 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370 (2014), 734–743.